Pesquisas alternativas:
after formed » after forced (Expandir a Pesquisa), after former (Expandir a Pesquisa), after informed (Expandir a Pesquisa)
formed phase » informed phase (Expandir a Pesquisa), armed phase (Expandir a Pesquisa), forms phase (Expandir a Pesquisa)
phase 1 » phase _ (Expandir a Pesquisa), phase 2 (Expandir a Pesquisa)
after formed » after forced (Expandir a Pesquisa), after former (Expandir a Pesquisa), after informed (Expandir a Pesquisa)
formed phase » informed phase (Expandir a Pesquisa), armed phase (Expandir a Pesquisa), forms phase (Expandir a Pesquisa)
phase 1 » phase _ (Expandir a Pesquisa), phase 2 (Expandir a Pesquisa)
201
Por Minnema, Amy Janelle, Mehta, A, Boling, Warren W, Schwab, Jan, Simard, J Marc, Farhadi, H Francis
Publicado no BMJ Open (2019)
“...) represents an increasingly well-characterised mechanism of secondary injury after tSCI that negatively...”Publicado no BMJ Open (2019)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
202
Por Ensoli, Barbara, Nchabeleng, Maphoshane, Ensoli, Fabrizio, Tripiciano, Antonella, Bellino, Stefania, Picconi, Orietta, Sgadari, Cecilia, Longo, Olimpia, Tavoschi, Lara, Joffe, Daniel, Cafaro, Aurelio, Francavilla, Vittorio, Moretti, Sonia, Pavone Cossut, Maria Rosaria, Collacchi, Barbara, Arancio, Angela, Paniccia, Giovanni, Casabianca, Anna, Magnani, Mauro, Buttò, Stefano, Levendal, Elise, Ndimande, John Velaphi, Asia, Bennett, Pillay, Yogan, Garaci, Enrico, Monini, Paolo
Publicado no Retrovirology (2016)
“... and transmission. Tat is expressed and released extracellularly by infected cells also under cART and in this form...”Publicado no Retrovirology (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
203
Por Desjardins, Annick, Randazzo, Dina, Chandramohan, Vidya, Peters, Katherine, Johnson, Margaret, Thomas, Leslie, Threatt, Stevie, Bullock, Chevelle, Herndon, James, Boulton, Susan, Healy, Patrick, Lipp, Eric, Sampson, John, Friedman, Allan, Friedman, Henry, Ashley, David, Bigner, Darell
Publicado no Neuro Oncol (2018)
“... report results of a phase 1 trial evaluating D2C7-IT delivered intratumorally by CED. METHODS: Eligible...”Publicado no Neuro Oncol (2018)
Obter o texto integral
Obter o texto integral
Artigo
204
Por Birkeland, Kåre I., Home, Philip D., Wendisch, Ulrich, Ratner, Robert E., Johansen, Thue, Endahl, Lars A., Lyby, Karsten, Jendle, Johan H., Roberts, Anthony P., DeVries, J. Hans, Meneghini, Luigi F.
Publicado em 2011
“...OBJECTIVE: Insulin degludec (IDeg) is a basal insulin that forms soluble multihexamers after...”Publicado em 2011
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
205
Por Rohatgi, Sarika, Ahuja, Vineet, Makharia, Govind K, Rai, Tarun, Das, Prasenjit, Dattagupta, Siddharth, Mishra, Veena, Garg, Sushil Kumar
Publicado no BMJ Open Gastroenterol (2015)
“...) A) or 1.6 g of mesalamine/day (Gp B) for 8 weeks in 30 patients with MC was conducted. After a...”Publicado no BMJ Open Gastroenterol (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
206
Por Obara, Wataru, Karashima, Takashi, Takeda, Kazuyoshi, Kato, Renpei, Kato, Yoichiro, Kanehira, Mitsugu, Takata, Ryo, Inoue, Keiji, Katagiri, Toyomasa, Shuin, Taro, Nakamura, Yusuke, Fujioka, Tomoaki
Publicado no Cancer Immunol Immunother (2016)
“...) corresponding to a part of HIG2 and applied it as a therapeutic vaccine. We conducted a phase I clinical trial...”Publicado no Cancer Immunol Immunother (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
207
Por Haense, N., Atmaca, A., Pauligk, C., Steinmetz, K., Marmé, F., Haag, G. M., Rieger, M., Ottmann, O. G., Ruf, P., Lindhofer, H., Al-Batran, S.-E.
Publicado no BMC Cancer (2016)
“... and the Fcγ-receptors I, IIa, and III forming a tri-cell complex between tumor cell, T cell and accessory...”Publicado no BMC Cancer (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
208
Por Yamada, Makiko, Uchiyama, Minoru, Inoue, Shin-Ichi, Deguchi, Tsuneo, Furuta, Yoshitake, Yabe, Koichi, Masuda, Nobuhisa
Publicado no Open Forum Infect Dis (2017)
“... and tolerable in its phase 1 study. The in vivo efficacy and physicochemical, pharmacokinetic, and toxicological...”Publicado no Open Forum Infect Dis (2017)
Obter o texto integral
Obter o texto integral
Artigo
209
Por Shi, Guang-Xia, Liu, Bao-Zhen, Wang, Jun, Fu, Qing-Nan, Sun, San-Feng, Liang, Rui-Li, Li, Jing, Tu, Jian-Feng, Tan, Cheng, Liu, Cun-Zhi
Publicado no J Pain Res (2018)
“...BACKGROUND: Strategies for preventing the persistence of pain and disability beyond the acute phase...”Publicado no J Pain Res (2018)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
210
Por O. O. Znoyko, M. V. Maevskaya, E. A. Klimova, S. L. Maksimov, S. N. Kizhlo, N. A. Petrochenkova, F. I. Nagimova, R. A. Ivanov, Yu. N. Linkova, T. V. Chernovskaya
Publicado em 2014-09-01
“.... Complete EVR (HCV RNA≤15 I I U/mL) was recorded in 88% and 84% of patients receiving Algeron 1,5 and 2,0 μg...”Publicado em 2014-09-01
Obter o texto integral
Artigo
211
Por Andtbacka, Robert H.I., Amatruda, Thomas, Nemunaitis, John, Zager, Jonathan S., Walker, John, Chesney, Jason A., Liu, Kate, Hsu, Cheng-Pang, Pickett, Cheryl A., Mehnert, Janice M.
Publicado no EBioMedicine (2019)
“... simplex virus type-1 oncolytic immunotherapy. The biodistribution, shedding, and potential transmission...”Publicado no EBioMedicine (2019)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
212
Por Khan, Akram, Benthin, Cody, Zeno, Brian, Albertson, Timothy E., Boyd, John, Christie, Jason D., Hall, Richard, Poirier, Germain, Ronco, Juan J., Tidswell, Mark, Hardes, Kelly, Powley, William M., Wright, Tracey J., Siederer, Sarah K., Fairman, David A., Lipson, David A., Bayliffe, Andrew I., Lazaar, Aili L.
Publicado no Crit Care (2017)
“.... In part A, open-label GSK2586881 was administered at doses from 0.1 mg/kg to 0.8 mg/kg to assess safety...”Publicado no Crit Care (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
213
Por Daltro, Gildasio Cerqueira, Fortuna, Vitor, de Souza, Eliane Silva, Salles, Marcela Miranda, Carreira, Ana Claudia, Meyer, Roberto, Freire, Songeli Menezes, Borojevic, Radovan
Publicado no Stem Cell Res Ther (2015)
“...) is still unclear. METHODS: We conducted a phase I/II, non-controlled study to determine efficacy and safety...”Publicado no Stem Cell Res Ther (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
214
“... are especially critical. Therefore, the train’s motion in such modes is limited by acceptable safety standards...”
Obter o texto integral
Obter o texto integral
Artigo
215
Por V. G. Akimkin, S. N. Kuzin, E. N. Kolosovskaya, E. N. Kudryavtceva, T. A. Semenenko, A. A. Ploskireva, D. V. Dubodelov, E. V. Tivanova, N. Yu. Pshenichnaya, A. V. Kalenskaya, S. V. Yatcishina, O. Yu. Shipulina, E. N. Rodionova, N. S. Petrova, I. V. Solov'eva, O. A. Kvasova, M. A. Vershinina, M. V. Mamoshina, V. V. Klushkina, M. I. Korabel'nikova, N. S. Churilova, Ya. V. Panasyuk, N. V. Vlasenko, A. A. Ostroushko, E. S. Balmasov, A. V. Mosunov
Publicado em 2021-11-01
“.../u.Results. After one year, the dynamics of reported cases of COVID-19 in St. Petersburg shows two cycles...”Publicado em 2021-11-01
Obter o texto integral
Artigo
216
BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: a first-in-human phase-I study
Por Miyamoto, Shingo, Yotsumoto, Fusanori, Ueda, Taeko, Fukami, Tatsuya, Sanui, Ayako, Miyata, Kohei, Nam, Sung Ouk, Fukagawa, Satoshi, Katsuta, Takahiro, Maehara, Miyako, Kondo, Haruhiko, Miyahara, Daisuke, Shirota, Kyoko, Yoshizato, Toshiyuki, Kuroki, Masahide, Nishikawa, Hiroaki, Saku, Keijiro, Tsuboi, Yoshio, Ishitsuka, Kenji, Takamatsu, Yasushi, Tamura, Kazuo, Matsunaga, Akira, Hachisuga, Toru, Nishino, Shinsuke, Odawara, Takashi, Maeda, Kazuhiro, Manabe, Sadao, Ishikawa, Toyokazu, Okuno, Yoshinobu, Ohishi, Minako, Hikita, Tomoya, Mizushima, Hiroto, Iwamoto, Ryo, Mekada, Eisuke
Publicado no BMC Cancer (2017)
“...BACKGROUND: BK-UM (CRM197) is a mutant form of diphtheria toxin and a specific inhibitor of heparin...”Publicado no BMC Cancer (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
217
Por Sandra Adela Naranjo Rodríguez, Rodobaldo García Menéndez, Lisandra Naranjo Rodríguez, Marisel Negret Hernández (1)
Publicado em 2011-04-01
Assuntos:
“...clinical trial phase II...”Publicado em 2011-04-01
Obter o texto integral
Artigo
218
“...The federal Conservative government recently began phasing in a plan to raise the age...”
Obter o texto integral
Obter o texto integral
Artigo
219
Por Strand, Vibeke, Kosinski, Mark, Chen, Chieh-I, Joseph, George, Rendas-Baum, Regina, Graham, Neil M. H., van Hoogstraten, Hubert, Bayliss, Martha, Fan, Chunpeng, Huizinga, Tom, Genovese, Mark C.
Publicado no Arthritis Res Ther (2016)
“... of the interleukin-6 receptor complex. In the MOBILITY phase III randomized controlled trial (RCT), sarilumab...”Publicado no Arthritis Res Ther (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
220
Por Zanini, Barbara, Benini, Federica, Pigozzi, Marie Graciella, Furba, Patrizia, Giacò, Ernesto, Cinquegrana, Antonia, Fasoli, Mariagrazia, Lanzini, Alberto
Publicado em 2013
“...AIM: To assess the acceptance, safety and efficacy of care and treatment for chronic hepatitis C...”Publicado em 2013
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo